A	B	C	D	E	F	G	H
1	Main
2		Brand Name	Crestor
3		Generic Name	rosuvastatin
4		Safety	NLA study concludes Crestor did not stand out relative to other statins
5		Economics	Shionogi
6		IP	IE case in USDC of DE. Judge Stark hearing SJ, Judge Farnar hearing patent.
7			COM RE37,314 issued 8/01, expires 7/8/16.					WPI received first final approval for generic on 6/12/2010.
8			MOU 6858618 expires 2022. Claims HeFH.
9			Salt 6316460 expires 2021. Claims salt and stability.
10		Clinical Trials
11			Phase III JUPITER n=15,000 - Terminated 3/31/2008 for efficacy
12			44% risk reduction in CV morbidity/mortality vs placebo, HR=0.56.
13			20% decrease in overall mortality.
14			Patient population had normal LDL (<130) but elevated hsCRP (>2).
15			Slight increase in diabetes.
16
17
18
19			METEOR study in Q4 - IVUS 24-month study of Crestor 40mg vs placebo n=800
20			ASTEROID - demonstrated 40mg Crestor could reduce the degree of arterial occlusion in partients with CAD - shrinkage achieved high SS
21			ORION - demonstrated 35.5% reduction in the lipid-rich necrotic core using MRI in n=39
22			AURORA
23			CORONA
24			EXPLORER - Crestor+Zetia vs Crestor alone
25			M05-748, n=1250, Crestor+ABT-335 - Study start March 06
26			M05-749, n=560, simvastatin+ABT-335 - n=560 start in March 2006
27			M05-750, n=560, lipitor+abt-335, start in march 2005
28			M05-758, n=2370, crestor+ vs simva+ vs lipitor+ starts in may 2006